BILLERICA, Mass., Dec. 13, 2018 /PRNewswire/ -- Bruker Corporation
and Mestrelab Research SL (www.mestrelab.com) today announced
that they have entered into a strategic partnership to advance
chemistry software that handles spectroscopic data and extracts and
manages chemical information from a variety of analytical
techniques, including for example NMR and mass spectrometry.
Together the companies will focus on pharmaceutical,
biotechnology, chemical and other industrial applications, as well
as on academic, and selected applied and clinical research
markets. Bruker and Mestrelab intend to collaborate closely
on the further development and commercialization of chemical
knowledge extraction and management software tools, as well as on
various novel and advanced workflow solutions, e.g. for medicinal
chemistry, organic molecule structure elucidation, industrial
applications of analytical chemistry techniques, etc.
As part of this new strategic collaboration, Bruker has become a
majority shareholder of Mestrelab, and will be represented on
Mestrelab's board of directors. Mestrelab will continue to be
managed by its founders and previous senior management team, and it
will continue to provide vendor-agnostic software solutions.
Financial details of the strategic collaboration were not
disclosed.
Mestrelab is based in Santiago
de Compostela, Spain, with direct
scientific software sales and support capabilities throughout
Europe and North America, and with experienced software
distributors in Japan,
China and many other
countries. Mestrelab was founded in 2004, and today has
approximately 40 employees developing software for over 3,000
pharmaceutical, chemical industry and academic customers, with more
than 100,000 user software licenses deployed worldwide.
Mestrelab is an agile and experienced developer of advanced
software solutions and tools for the pharmaceutical, analytical and
scientific research community to enhance the management and
understanding of chemistry information.
The new strategic partnership supports a closer integration of a
wide range of analytical instrumentation and systems with data
post-processing, information extraction, as well as data and
chemistry knowledge management software. This will deliver
higher research productivity and better answers to end users, with
applications in a wide range of fields, from pharmaceutical,
biotech and chemistry R&D, to manufacturing and supply chain
quality control, as well as applied markets.
Dr. Falko Busse, President of
Bruker BioSpin Group, stated: "This new strategic collaboration and
investment aligns the natural synergies between our two companies
to deliver more comprehensive capabilities and future novel
workflow solutions to our customers. Integrating the
well-established software of Mestrelab with Bruker's existing NMR
systems and solutions allows us to further develop end-to-end
solutions for customers in pharmaceutical, industrial and applied
market segments, as well as in our core academic markets."
Mr. Santiago Dominguez, CEO of
Mestrelab, commented: "We are very excited to be able to join
forces with a world-leading scientific instruments company, so that
both teams can focus on delivering where their efforts can be most
beneficial for the pharma and chemistry community.
Comprehensive analytical data measurement, automated
evaluation and fast delivery of results show great potential to
improve processes and outcomes, and apply new techniques for data
sharing, data processing and analysis, automation, big data
building, machine and deep learning techniques."
Bruker and Mestrelab will develop and deliver fully integrated
solutions to specific pharma, chemical and applied markets
problems, and will aim for seamless integration of data acquisition
and post-processing, chemical information extraction and knowledge
management in order to optimize productivity and to provide better
answers.
About Mestrelab Research SL
Mestrelab develops software solutions designed to accelerate
R&D in a number of industries, including pharmaceutical,
biotechnology, chemical and other industrial applications.
Mestrelab develops tools for the handling of analytical data from a
variety of techniques and vendors, as well as solutions to enhance
the management and understanding of chemistry information. For more
information: www.mestrelab.com
About Bruker Corporation (NASDAQ: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker's high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research and clinical microbiology. For more
information: www.bruker.com.
Investor Relations Contact Bruker
Miroslava Minkova
Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: miroslava.minkova@bruker.com
Media Contact Bruker
Thorsten
Thiel, Ph.D.
VP of Group Marketing
T: +49 (721) 5161–6500
E: thorsten.thiel@bruker.com
Media Contact Mestrelab Research
SL
Santiago Dominguez
CEO
T: +44-7815799765
E: sdominguez@mestrelab.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bruker-and-mestrelab-announce-strategic-collaboration-and-partnership-for-chemistry-and-pharma-software-applications-300764832.html
SOURCE Bruker Corporation